^
Association details:
| Biomarker: | BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report
Published date:
11/17/2021
Excerpt:
...the case of a patient with BRAF V600E, PIK3CA, and SMAD4 mutated and dMMR/MSI mCRC...The patient was progressive after a single cycle of pembrolizumab followed by a rapid complete response after only 2 months of treatment with encorafenib and cetuximab...
DOI:
10.1002/gcc.23012
